Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters

January 2, 2024

https://www.prnewswire.com/news-releases/citius-pharmaceuticals-completes-enrollment-in-pivotal-phase-3-trial-of-its-mino-lok-therapeutic-to-salvage-catheters-302024218.html

Topline results expected 2Q 2024

Study enrolled a total of 241 patients; 109 catheter failures observed

First-and-only antibiotic lock solution in development to salvage catheters in patients with CRBSI

Read more at prnewswire.com

Related news for (CTXR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.